文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

川崎病中的静脉注射免疫球蛋白抵抗:临床和实验室风险因素以及给药时机的潜在作用

IVIG Resistance in Kawasaki Disease: Clinical and Laboratory Risk Factors and the Potential Role of Administration Timing.

作者信息

Peng Yue, Jing Fengchuan, Liu Dong, Li Bin, Xu Yanxia, Tan Zhongyou, Chen Ouyang, Yang Yanfeng, Si Feifei, Jiang Wenliang, Li Cong, Cheng Zhenli, Zhou Xue, Feng Siqi, Su Ya, Yi Qijian

机构信息

Department of Cardiovascular Medicine, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, People's Republic of China.

Chongqing Key Laboratory of Structural Birth Defect and Reconstruction, Chongqing, People's Republic of China.

出版信息

J Inflamm Res. 2025 May 2;18:5923-5929. doi: 10.2147/JIR.S513963. eCollection 2025.


DOI:10.2147/JIR.S513963
PMID:40337548
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12056523/
Abstract

OBJECTIVE: Intravenous immunoglobulin (IVIG) resistance is associated with coronary artery abnormalities in Kawasaki disease (KD) and requires additional therapy. The purpose of this study was to determine independent risk factors for IVIG resistance, investigate the response to IVIG treatment at different time points and determine whether the time option of IVIG treatment altered IVIG resistance. METHODS: The clinical data of 6264 KD patients in southwest China were analyzed retrospectively. According to the response to IVIG treatment, the patients were divided into IVIG response group and IVIG resistance group. Multiple logistic regression model was used to identify independent risk factors for IVIG resistance, and trend chi-square test was used to examine the effect of IVIG timing on IVIG resistance. RESULTS: Multivariate analysis showed that IVIG time, WBC, PLT, HB, ALT and Na were independently associated with IVIG resistance, and IVIG time was a key variable for IVIG resistance. In addition, these data suggested that the rate of IVIG resistance was the lowest when treated with IVIG on the seventh and eighth day of initial fever. CONCLUSION: IVIG timing is a key factor in IVIG resistance. Our data suggest a lower resistance rate when IVIG is administered on the seventh and eighth day of initial fever. However, the clinical implications of delaying treatment are uncertain, and early IVIG administration remains essential to prevent cardiovascular complications. Further research is needed to validate these findings and to guide clinical practice.

摘要

目的:静脉注射免疫球蛋白(IVIG)抵抗与川崎病(KD)的冠状动脉异常相关,需要额外治疗。本研究的目的是确定IVIG抵抗的独立危险因素,调查不同时间点对IVIG治疗的反应,并确定IVIG治疗的时间选择是否会改变IVIG抵抗。 方法:回顾性分析中国西南部6264例KD患者的临床资料。根据对IVIG治疗的反应,将患者分为IVIG反应组和IVIG抵抗组。采用多因素logistic回归模型确定IVIG抵抗的独立危险因素,采用趋势卡方检验分析IVIG治疗时机对IVIG抵抗的影响。 结果:多因素分析显示,IVIG治疗时间、白细胞(WBC)、血小板(PLT)、血红蛋白(HB)、谷丙转氨酶(ALT)和血钠(Na)与IVIG抵抗独立相关,且IVIG治疗时间是IVIG抵抗的关键变量。此外,这些数据表明,在初次发热的第7天和第8天接受IVIG治疗时,IVIG抵抗率最低。 结论:IVIG治疗时机是IVIG抵抗的关键因素。我们的数据表明,在初次发热的第7天和第8天给予IVIG时抵抗率较低。然而,延迟治疗的临床意义尚不确定,早期给予IVIG对于预防心血管并发症仍然至关重要。需要进一步研究来验证这些发现并指导临床实践。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbe8/12056523/3ca998033062/JIR-18-5923-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbe8/12056523/3ca998033062/JIR-18-5923-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbe8/12056523/3ca998033062/JIR-18-5923-g0001.jpg

相似文献

[1]
IVIG Resistance in Kawasaki Disease: Clinical and Laboratory Risk Factors and the Potential Role of Administration Timing.

J Inflamm Res. 2025-5-2

[2]
Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.

Clin Rheumatol. 2023-1

[3]
Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.

Pediatr Neonatol. 2014-10

[4]
Serum alanine aminotransferase level and intravenous immunoglobulin resistance in patients with kawasaki disease.

Clin Rheumatol. 2022-10

[5]
[Association between duration of fever before treatment and intravenous immunoglobulin resistance in Kawasaki disease].

Zhongguo Dang Dai Er Ke Za Zhi. 2022-4-15

[6]
Predictive role of sampling-time specific prognostic nutritional index cut-off values for intravenous immunoglobulin resistance and cardiovascular complications in Kawasaki disease.

Int Immunopharmacol. 2022-9

[7]
Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.

Turk J Pediatr. 2019

[8]
Clinical features analysis of Kawasaki disease with abdominal symptoms as the first manifestation.

Eur J Pediatr. 2023-9

[9]
Sodium-containing versus sodium-trace preparations of IVIG for children with Kawasaki disease in the acute phase.

Eur J Pediatr. 2021-11

[10]
Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.

Lancet Child Adolesc Health. 2018-10-16

本文引用的文献

[1]
Kawasaki Disease: A Never-ending Story?

Eur Cardiol. 2023-7-27

[2]
Prediction Models for Intravenous Immunoglobulin Resistance in Kawasaki Disease: A Meta-analysis.

Pediatrics. 2023-5-1

[3]
Failure of Risk Prediction Modeling for IVIG Resistance in Kawasaki Disease.

Pediatrics. 2023-5-1

[4]
Intravenous immunoglobulin resistance in Kawasaki disease patients: prediction using clinical data.

Pediatr Res. 2024-2

[5]
Incidence and timing of coronary thrombosis in Kawasaki disease patients with giant coronary artery aneurysm.

Thromb Res. 2023-1

[6]
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.

Lancet Child Adolesc Health. 2021-12

[7]
Refractory Kawasaki disease: diagnostic and management challenges.

Pediatric Health Med Ther. 2019-10-30

[8]
The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.

Pediatr Rheumatol Online J. 2019-7-31

[9]
Association of Severity of Coronary Artery Aneurysms in Patients With Kawasaki Disease and Risk of Later Coronary Events.

JAMA Pediatr. 2018-5-7

[10]
Effect of i.v. immunoglobulin in the first 4 days of illness in Kawasaki disease.

Pediatr Int. 2018-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索